**Table S1 Included Studies**

| Author | Sample size | Main virus strains | Newcastle–Ottawa quality assessment scale | Countries |
|---|---|---|---|---|
| Ahmet Naci Emecen[1] | 5083 | Omicron | low | Turkey |
| Aleksander Och[2] | 79 | Omicron | low | Poland |
| Anna Lindahl[3] | 101 | Wild | low | Finland |
| Beatriz CostaTodt[4] | 251 | Wild | low | Brazil |
| Christoph Becker[5] | 90 | Wild | low | Switzerland |
| Dai S[6] | 50 | Wild | moderate | China |
| Damiano Caruso[7] | 118 | Wild | low | Italy |
| Daniel CruzBretasaArnaldo[8] | 211 | Gamma | low | Brazil |
| Daniele Noviello[9] | 164 | Wild | low | Italy |
| Danilo Buonsenso[10] | 245 | Omicron | low | Italy |
| David Zuschlag[11] | 162 | Delta | low | Germany |
| Dominik Menges[12] | 431 | Wild | low | Switzerland |
| Elena Tessitore[13] | 184 | Wild | low | Switzerland |
| Fangyuan Zhou[14] | 120 | Wild | low | China |
| Florian Desgranges[15] | 418 | Wild | moderate | Switzerland |
| Förster[16] | 1459 | Wild | moderate | Germany |
| G Shiny Chrism Queen Nesan[17] | 1354 | Delta | low | India |
| Gabriele da Silveira Prestes[18] | 44 | Wild | low | Brazil |
| GeorgeCalcaianua[19] | 320 | Wild | low | France |
| Gianna Vargas Centanaro[20] | 305 | Wild | low | Spain |
| Gonzalo Labarca[21] | 60 | Wild | low | Chile |
| Hadar Klein[22] | 103 | Wild | moderate | Israel |
| Ignacio Martin-Loeches[23] | 991 | Wild | low | Spain |
| Jessica González[24] | 62 | Wild | moderate | Spain |
| Judit Aranda[25] | 113 | Wild | low | Spain |
| Jun Zhang[26] | 248 | Wild | low | China |
| Justin R. Kingery[27] | 530 | Wild | low | United States of America |
| K Zhan[28] | 311 | Wild | low | China |
| KWMiskowiak[29] | 25 | Wild | low | Denmark |
| LouiseSigfrid[30] | 327 | Alpha | low | United Kingdom |
| Maddalena Peghin[31] | 599 | Wild | low | Italy |
| Marco Colizzi[32] | 479 | Wild | low | Italy |
| Marie Vejen[33] | 128 | Alpha | moderate | Denmark |
| Marina Aiello[34] | 121 | Delta | low | Italy |
| Mario Rivera-Izquierdo[35] | 453 | Wild | low | Spain |
| Marta Rigoni[36] | 471 | Wild | low | Italy |

| | | | | |
|---|---|---|---|---|
| Martin Mølhave[37] | 45 | Wild | low | Denmark |
| Miriam Hernández Porto[38] | 72 | Wild | low | Spain |
| Mohamed Attauabi[39] | 222 | Omicron | low | Denmark |
| Mohammad Anwar Hossain[40] | 2198 | Beta | low | Bangladesh |
| Philippine ELOY[41] | 324 | Alpha | low | France |
| Priya Duggal[42] | 328 | Wild | low | United States of America |
| Ramos-Sánchez Mónica[43] | 305 | Wild | low | Spain |
| Raphael S. Peter[44] | 11710 | Omicron | low | Germany |
| Rebecca C. Robey[45] | 221 | Wild | low | United Kingdom |
| Ricardo Titze-de-Almeida[46] | 236 | Wild | low | Brazil |
| Souheil Zayet[47] | 354 | Wild | low | France |
| Xuejiao Liao[48] | 273 | Wild | low | China |
| Yumin Li[49] | 141 | Wild | low | China |
| Álvaro Aparisi[50] | 70 | Wild | low | Spain |
| Álvaro Romero-Duarte[51] | 797 | Wild | low | Spain |

**Table S2. Pooled prevalence of COVID-19 consequences at follow-up 3 months and above**

| Consequences | Number of Studies | Patients n/N | PP (95%CI, %) | p-value | I2 | p-value for Egger regression test |
|---|---|---|---|---|---|---|
| **General symptoms** | | | | | | |
| ≥1 Symptoms | 24 | 5121/12870 | 51.1 (41.4, 60.8) | <0.05 | 99.2% | 0.2394 |
| Fever or Feverishness | 13 | 289/15540 | 2.7 (1.9, 3.6) | <0.05 | 92.3% | <0.0001 |
| Fatigue | 26 | 5520/25062 | 29.8 (24.4, 35.1) | <0.05 | 99.1% | 0.01 |
| Muscle weakness | 6 | 142/3329 | 4.9 (2.8, 7.0) | <0.05 | 96.5% | <0.0001 |
| Myalgia | 16 | 1724/15944 | 10.9 (7.6, 14.3) | <0.05 | 98.5% | 0.0008 |
| Joint pain or arthralgia | 9 | 2290/12635 | 18.5 (13.5, 23.5) | <0.05 | 93.7% | 0.0718 |
| Headache | 28 | 3985/27799 | 10.6 (7.8, 13.3) | <0.05 | 99.4% | 0.0001 |
| Dizziness or Vertigo | 10 | 2199/9334 | 3.5 (1.8, 5.2) | <0.05 | 96.2% | <0.0001 |
| Olfactory abnormalities | 8 | 2697/16896 | 9.1 (0.7, 17.5) | <0.05 | 99.6% | 0.6648 |
| Olfactory loss | 11 | 503/5301 | 13.2 (9.1, 17.3) | <0.05 | 97.1% | 0.006 |
| Taste abnormalities | 7 | 2070/16793 | 8.3 (0.9, 15.6) | <0.05 | 99.6% | 0.3641 |
| Taste loss | 11 | 445/7590 | 8.9 (6.1, 11.6) | <0.05 | 97.4% | <0.0001 |
| Hair loss | 9 | 1781/14037 | 9.6 (4.7, 14.4) | <0.05 | 98.6% | 0.0204 |
| Cutaneous or Skin disorders | 6 | 156/3738 | 3.9 (2.1, 5.7) | <0.05 | 88.3% | 0.3123 |
| Rash | 5 | 666/16548 | 3.3 (0.4, 6.1) | <0.05 | 99.3% | 0.2735 |
| **Respiratory symptoms** | | | | | | |
| Cough | 27 | 2447/24229 | 13.3 (10.6, 16.0) | <0.05 | 98.8% | <0.0001 |
| Gamma | 1 | 34/156 | 21.8 (15.3, 28.3) | <0.05 | - | |
| Dyspnea | 27 | 2105/16467 | 21.2 (17.7, 24.7) | <0.05 | 99.1% | <0.0001 |
| Gamma | 1 | 68/158 | 43.0 (35.3, 50.8) | <0.05 | - | |
| Expectoration | 5 | 80/998 | 7.5 (2.9, 12.1) | <0.05 | 94.8% | 0.012 |
| Nasal congestion | 7 | 105/6011 | 3.4 (1.8, 5.1) | <0.05 | 93.2% | 0.0409 |
| Sore throat | 7 | 1045/18159 | 4.3 (1.3, 7.4) | <0.05 | 99.4% | 0.0287 |
| mMRC = 0 | 6 | 799/1317 | 50.6 (28.0, 73.2) | <0.05 | 98.9% | 0.0187 |
| mMRC≥1 | 8 | 590/1510 | 46.2 (28.1, 64.2) | <0.05 | 98.5% | 0.114 |
| **Cardiovascular symptoms** | | | | | | |
| Short Breath | 8 | 3848/13202 | 23.1 (12.1, 34.0) | <0.05 | 99.2% | 0.1063 |
| Palpitations | 13 | 285/9764 | 3.8 (2.6, 5.0) | <0.05 | 93.8% | <0.0001 |
| **Gastrointestinal symptoms** | | | | | | |
| ≥1 symptoms | 5 | 35/1603 | 1.8 (0.2, 3.3) | <0.05 | 84.3% | <0.0001 |
| Loss of appetite | 8 | 107/2710 | 3.6 (1.8, 5.3) | <0.05 | 84.7% | <0.0001 |
| Nausea | 6 | 520/12225 | 3.6 (1.1, 6.0) | <0.05 | 95.7% | <0.0001 |
| Diarrhea | 10 | 121/3222 | 2.6 (1.3, 3.9) | <0.05 | 90.9% | 0.0292 |
| Abdominal pain | 9 | 694/18327 | 2.6 (0.7, 4.5) | <0.05 | 98.7% | 0.1204 |
| Constipation | 5 | 99/2969 | 4.1 (2.0, 6.2) | <0.05 | 92.4% | <0.0001 |
| **Neurological and psychiatric symptoms** | | | | | | |
| ≥1 Neurological symptoms | 8 | 371/2950 | 13.8 (8.5, 19.2) | <0.05 | 95.7% | 0.0037 |

| | | | | | | |
|---|---|---|---|---|---|---|
| Paresthesias | 9 | 1504/14363 | 11.4 (6.5, 16.4) | <0.05 | 99.2% | <0.0001 |
| Memory problem | 7 | 2019/12663 | 16.8 (10.3, 23.3) | <0.05 | 97.8% | 0.005 |
| Sleep difficulty | 18 | 3758/21121 | 21.8 (16.2, 27.4) | <0.05 | 99.6% | <0.0001 |
| Depression | 11 | 2686/14896 | 17.9 (10.3, 25.5) | <0.05 | 99.4% | 0.4603 |
| Anxiety | 13 | 1639/14470 | 13.5 (9.5, 17.4) | <0.05 | 97.8% | 0.0792 |
| Difficulty concentrating | 8 | 3912/18093 | 22.3 (8.8, 35.8) | <0.05 | 99.9% | 0.0094 |
| **PFT** | | | | | | |
| FEV1<80% | 5 | 70/425 | 16.5 (9.0, 24.0) | <0.05 | 78.7% | 0.0552 |
| TLC<80% | 6 | 204/828 | 27.0 (13.1, 41.0) | <0.05 | 96.4% | 0.0961 |
| DLCO<80% | 6 | 866/1413 | 56.9 (40.6, 73.1) | <0.05 | 96.3% | 0.7422 |
| **CT results** | | | | | | |
| CT abnormalities | 11 | 1540/2206 | 60.5 (40.4, 80.6) | <0.05 | 99.2% | 0.4432 |
| GGO | 12 | 403/1231 | 38.9 (26.8, 51.0) | <0.05 | 95.7% | 0.1506 |
| Consolidation | 5 | 21/388 | 5.4 (0.8, 9.9) | <0.05 | 80.6% | 0.0002 |
| Fibrosis | 9 | 340/1790 | 24.4 (13.3, 35.4) | <0.05 | 96.3% | 0.8744 |
| Bronchiectasis | 7 | 195/892 | 22.2 (9.7, 34.7) | <0.05 | 96.6% | 0.0136 |
| **EQ-5D-5L** | | | | | | |
| Mobility | 5 | 192/1038 | 24.0 (12.9, 35.1) | <0.05 | 95.7% | 0.0159 |
| Personal care | 4 | 73/911 | 14.8 (7.0, 22.5) | <0.05 | 97.8% | <0.0001 |
| Usual activity | 4 | 185/796 | 33.5 (13.1, 53.9) | <0.05 | 97.6% | 0.0015 |
| Pain or discomfort | 5 | 430/1039 | 48.6 (35.4, 61.7) | <0.05 | 94.6% | <0.0001 |
| Anxiety and depression | 5 | 346/1014 | 36.7 (14.9, 58.5) | <0.05 | 98.9% | <0.0001 |

Notes: mMRC: Modified Medical Research Council Dyspnea Scale; PFT: Pulmonary functional test; FEV1: Forced expiratory volume in one second; TLC: Total lung capacity; DLCO: Carbon monoxide diffusing capacity; CT: Computerized tomography; GGO: Ground-glass opacity; EQ-5D-5L: Quality of life evaluation.

References


1. Emecen, A.N.; Keskin, S.; Turunc, O.; Suner, A.F.; Siyve, N.; Basoglu Sensoy, E.; Dinc, F.; Kilinc, O.; Avkan Oguz, V.; Bayrak, S., et al. The presence of symptoms within 6 months after COVID-19: a single-center longitudinal study. *Irish Journal of Medical Science* **2022**, 10.1007/s11845-022-03072-0, doi:10.1007/s11845-022-03072-0.
2. Och, A.; Tylicki, P.; Polewska, K.; Puchalska-Reglińska, E.; Parczewska, A.; Szabat, K.; Biedunkiewicz, B.; Dębska-ślizień, A.; Tylicki, L. Persistent post-covid-19 syndrome in hemodialyzed patients—a longitudinal cohort study from the North of Poland. *Journal of Clinical Medicine* **2021**, *10*, doi:10.3390/jcm10194451.
3. Lindahl, A.; Aro, M.; Reijula, J.; Mäkelä, M.J.; Ollgren, J.; Puolanne, M.; Järvinen, A.; Vasankari, T. Women report more symptoms and impaired quality of life: a survey of Finnish COVID-19 survivors. *Infectious Diseases* **2022**, *54*, 53-62, doi:10.1080/23744235.2021.1965210.
4. Todt, B.C.; Szlejf, C.; Duim, E.; Linhares, A.O.M.; Kogiso, D.; Varela, G.; Campos, B.A.; Baghelli Fonseca, C.M.; Polesso, L.E.; Bordon, I.N.S., et al. Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge. *Respiratory Medicine* **2021**, *184*, 106453, doi:https://doi.org/10.1016/j.rmed.2021.106453.
5. Becker, C.; Beck, K.; Zumbrunn, S.; Memma, V.; Herzog, N.; Bissmann, B.; Gross, S.; Loretz, N.; Mueller, J.; Amacher, S.A., et al. Long COVID 1 year after hospitalisation for COVID-19: a prospective bicentric cohort study. *Swiss Medical Weekly* **2021**, *151*, doi:10.4414/SMW.2021.W30091.
6. Dai, S.; Zhao, B.; Liu, D.; Zhou, Y.; Liu, Y.; Lan, L.; Li, Y.; Luo, W.; Zeng, Y.; Li, W. Follow-up study of the cardiopulmonary and psychological outcomes of covid-19 survivors six months after discharge in sichuan, china. *International Journal of General Medicine* **2021**, *14*, 7207-7217, doi:10.2147/IJGM.S337604.
7. Caruso, D.; Guido, G.; Zerunian, M.; Polidori, T.; Lucertini, E.; Pucciarelli, F.; Polici, M.; Rucci, C.; Bracci, B.; Nicolai, M., et al. Post-acute sequelae of COVID-19 pneumonia: Six-month chest CT follow-up. *Radiology* **2021**, *301*, E36-E405, doi:10.1148/radiol.2021210834.
8. Bretas, D.C.; Leite, A.S.; Mancuzo, E.V.; Prata, T.A.; Andrade, B.H.; Oliveira, J.D.G.F.; Batista, A.P.; Machado-Coelho, G.L.L.; Augusto, V.M.; Marinho, C.C. Lung function six months after severe COVID-19: Does time, in fact, heal all wounds? *Brazilian Journal of Infectious Diseases* **2022**, *26*, doi:10.1016/j.bjid.2022.102352.
9. Noviello, D.; Costantino, A.; Muscatello, A.; Bandera, A.; Consonni, D.; Vecchi, M.; Basilisco, G. Functional Gastrointestinal And Somatoform Symptoms Five Months After Sars-Cov-2 Infection: A Controlled Cohort Study. *Digestive and Liver Disease* **2021**, *53*, S119-S120, doi:10.1016/S1590-8658(21)00530-2.
10. Buonsenso, D.; Munblit, D.; Pazukhina, E.; Ricchiuto, A.; Sinatti, D.; Zona, M.; De Matteis, A.; D'Ilario, F.; Gentili, C.; Lanni, R., et al. Post-COVID Condition in Adults and Children Living in the Same Household in Italy: A Prospective Cohort Study Using the ISARIC Global Follow-Up Protocol. *Frontiers in Pediatrics* **2022**, *10*, doi:10.3389/fped.2022.834875.
11. Zuschlag, D.; Grandt, D.; Custodis, F.; Braun, C.; Häuser, W. Spontaneously reported

persistent symptoms related to coronavirus disease 2019 one year after hospital discharge : A retrospective cohort single-center study. *Schmerz* **2022**, 10.1007/s00482-022-00626-0, 1-9, doi:10.1007/s00482-022-00626-0.

12. Menges, D.; Ballouz, T.; Anagnostopoulos, A.; Aschmann, H.E.; Domenghino, A.; Fehr, J.S.; Puhan, M.A. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. *PLoS ONE* **2021**, *16*, doi:10.1371/journal.pone.0254523.
13. Tessitore, E.; Handgraaf, S.; Poncet, A.; Achard, M.; Höfer, S.; Carballo, S.; Marti, C.; Follonier, C.; Girardin, F.; Mach, F., et al. Symptoms and quality of life at 1-year follow up of patients discharged after an acute COVID-19 episode. *Swiss Medical Weekly* **2021**, *151*, doi:10.4414/SMW.2021.W30093.
14. Zhou, F.; Tao, M.; Shang, L.; Liu, Y.; Pan, G.; Jin, Y.; Wang, L.; Hu, S.; Li, J.; Zhang, M., et al. Assessment of Sequelae of COVID-19 Nearly 1 Year After Diagnosis. *Frontiers in Medicine* **2021**, *8*, doi:10.3389/fmed.2021.717194.
15. Desgranges, F.; Tadini, E.; Munting, A.; Regina, J.; Filippidis, P.; Viala, B.; Karachalias, E.; Suttels, V.; Haefliger, D.; Kampouri, E., et al. Post‐COVID‐19 Syndrome in Outpatients: a Cohort Study. *Journal of General Internal Medicine* **2022**, *37*, 1943-1952, doi:10.1007/s11606-021-07242-1.
16. Förster, C.; Colombo, M.G.; Wetzel, A.J.; Martus, P.; Joos, S. Persisting Symptoms after COVID-19: Prevalence and Risk Factors in a Population-Based Cohort. *Deutsches Arzteblatt International* **2022**, *119*, 167-174, doi:10.3238/arztebl.m2022.0147.
17. Nesan, G.S.C.Q.; Keerthana, D.; Yamini, R.; Jain, T.; Kumar, D.; Eashwer, A.; Maiya, G.R. 3-Month Symptom-Based Ambidirectional Follow-up Study Among Recovered COVID-19 Patients from a Tertiary Care Hospital Using Telehealth in Chennai, India. *Inquiry : a journal of medical care organization, provision and financing* **2021**, *58*, 469580211060165, doi:10.1177/00469580211060165.
18. Prestes, G.D.S.; Simon, C.S.; Walz, R.; Ritter, C.; Dal-Pizzol, F. Respiratory Outcomes After 6 Months of Hospital Discharge in Patients Affected by COVID-19: A Prospective Cohort. *Frontiers in Medicine* **2022**, *9*, doi:10.3389/fmed.2022.795074.
19. Calcaianu, G.; Degoul, S.; Michau, B.; Payen, T.; Gschwend, A.; Fore, M.; Iamandi, C.; Morel, H.; Oster, J.-P.; Bizieux, A., et al. Mid-term pulmonary sequelae after hospitalisation for COVID-19: the French SISCOVID cohort. *Respiratory Medicine and Research* **2022**, https://doi.org/10.1016/j.resmer.2022.100933, 100933, doi:https://doi.org/10.1016/j.resmer.2022.100933.
20. Vargas Centanaro, G.; Calle Rubio, M.; Álvarez-Sala Walther, J.L.; Martinez-Sagasti, F.; Albuja Hidalgo, A.; Herranz Hernández, R.; Rodríguez Hermosa, J.L. Long-term Outcomes and Recovery of Patients who Survived COVID-19: LUNG INJURY COVID-19 Study. *Open Forum Infectious Diseases* **2022**, *9*, doi:10.1093/ofid/ofac098.
21. Labarca, G.; Henríquez-Beltrán, M.; Lastra, J.; Enos, D.; Llerena, F.; Cigarroa, I.; Lamperti, L.; Ormazabal, V.; Ramirez, C.; Espejo, E., et al. Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19. *Clinical Respiratory Journal* **2021**, *15*, 992-1002, doi:10.1111/crj.13403.
22. Klein, H.; Asseo, K.; Karni, N.; Benjamini, Y.; Nir-Paz, R.; Muszkat, M.; Israel, S.; Niv, M.Y. Onset, duration and unresolved symptoms, including smell and taste changes, in mild

COVID-19 infection: a cohort study in Israeli patients. *Clinical Microbiology and Infection* **2021**, *27*, 769-774, doi:https://doi.org/10.1016/j.cmi.2021.02.008.
23. Martin-Loeches, I.; Motos, A.; Menéndez, R.; Gabarrús, A.; González, J.; Fernández-Barat, L.; Ceccato, A.; Pérez-Arnal, R.; García-Gasulla, D.; Ferrer, R., et al. ICU-Acquired Pneumonia Is Associated with Poor Health Post-COVID-19 Syndrome. *Journal of Clinical Medicine* **2022**, *11*, doi:10.3390/jcm11010224.
24. González, J.; Benítez, I.D.; Carmona, P.; Santisteve, S.; Monge, A.; Moncusí-Moix, A.; Gort-Paniello, C.; Pinilla, L.; Carratalá, A.; Zuil, M., et al. Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. *Chest* **2021**, *160*, 187-198, doi:10.1016/j.chest.2021.02.062.
25. Aranda, J.; Oriol, I.; Martín, M.; Feria, L.; Vázquez, N.; Rhyman, N.; Vall-Llosera, E.; Pallarés, N.; Coloma, A.; Pestaña, M., et al. Long-term impact of COVID-19 associated acute respiratory distress syndrome. *Journal of Infection* **2021**, *83*, 581-588, doi:10.1016/j.jinf.2021.08.018.
26. Zhang, J.; Shu, T.; Zhu, R.; Yang, F.; Zhang, B.; Lai, X. The Long-Term Effect of COVID-19 Disease Severity on Risk of Diabetes Incidence and the Near 1-Year Follow-Up Outcomes among Postdischarge Patients in Wuhan. *Journal of Clinical Medicine* **2022**, *11*, doi:10.3390/jcm11113094.
27. Kingery, J.R.; Safford, M.M.; Martin, P.; Lau, J.D.; Rajan, M.; Wehmeyer, G.T.; Li, H.A.; Alshak, M.N.; Jabri, A.; Kofman, A., et al. Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection. *Journal of General Internal Medicine* **2022**, *37*, 1218-1225, doi:10.1007/s11606-021-07379-z.
28. Zhan, K.; Zhang, X.; Wang, B.; Jiang, Z.; Fang, X.; Yang, S.; Jia, H.; Li, L.; Cao, G.; Zhang, K., et al. Short-and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes. *QJM* **2022**, *115*, 131-139, doi:10.1093/qjmed/hcac020.
29. Miskowiak, K.W.; Fugledalen, L.; Jespersen, A.E.; Sattler, S.M.; Podlekareva, D.; Rungby, J.; Porsberg, C.M.; Johnsen, S. Trajectory of cognitive impairments over 1 year after COVID-19 hospitalisation: Pattern, severity, and functional implications. *European Neuropsychopharmacology* **2022**, *59*, 82-92, doi:10.1016/j.euroneuro.2022.04.004.
30. Sigfrid, L.; Drake, T.M.; Pauley, E.; Jesudason, E.C.; Olliaro, P.; Lim, W.S.; Gillesen, A.; Berry, C.; Lowe, D.J.; McPeake, J., et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *The Lancet Regional Health - Europe* **2021**, *8*, 100186, doi:https://doi.org/10.1016/j.lanepe.2021.100186.
31. Peghin, M.; Palese, A.; Venturini, M.; De Martino, M.; Gerussi, V.; Graziano, E.; Bontempo, G.; Marrella, F.; Tommasini, A.; Fabris, M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. *Clinical Microbiology and Infection* **2021**, *27*, 1507-1513, doi:10.1016/j.cmi.2021.05.033.
32. Colizzi, M.; Peghin, M.; De Martino, M.; Bontempo, G.; Gerussi, V.; Palese, A.; Isola, M.; Tascini, C.; Balestrieri, M. Mental health symptoms one year after acute COVID-19 infection: Prevalence and risk factors. *Revista de Psiquiatría y Salud Mental* **2022**, https://doi.org/10.1016/j.rpsm.2022.05.008, doi:https://doi.org/10.1016/j.rpsm.2022.05.008.
33. Vejen, M.; Hansen, E.F.; Al-Jarah, B.N.I.; Jensen, C.; Thaning, P.; Jeschke, K.N.; Ulrik, C.S.

Hospital admission for COVID-19 pneumonitis - long-term impairment in quality of life and lung function. *Eur Clin Respir J* **2022**, *9*, 2024735, doi:10.1080/20018525.2021.2024735.

34. Aiello, M.; Marchi, L.; Calzetta, L.; Speroni, S.; Frizzelli, A.; Ghirardini, M.; Celiberti, V.; Sverzellati, N.; Majori, M.; Mori, P.A., et al. Coronavirus Disease 2019: COSeSco - A Risk Assessment Score to Predict the Risk of Pulmonary Sequelae in COVID-19 Patients. *Respiration* **2021**, 10.1159/000519385, doi:10.1159/000519385.
35. Rivera-Izquierdo, M.; Láinez-Ramos-Bossini, A.J.; de Alba, I.G.; Ortiz-González-Serna, R.; Serrano-Ortiz, Á.; Fernández-Martínez, N.F.; Ruiz-Montero, R.; Cervilla, J.A. Long COVID 12 months after discharge: persistent symptoms in patients hospitalised due to COVID-19 and patients hospitalised due to other causes-a multicentre cohort study. *BMC Med* **2022**, *20*, 92, doi:10.1186/s12916-022-02292-6.
36. Rigoni, M.; Torri, E.; Nollo, G.; Donne, L.D.; Rizzardo, S.; Lenzi, L.; Falzone, A.; Cozzio, S. "Long COVID" results after hospitalization for SARS-CoV-2 infection. *Scientific reports* **2022**, *12*, 9581, doi:10.1038/s41598-022-13077-5.
37. Mølhave, M.; Leth, S.; Gunst, J.D.; Jensen-Fangel, S.; Østergaard, L.; Wejse, C.; Agergaard, J. Long-term symptoms among hospitalized COVID-19 patients 48 weeks after discharge—A prospective cohort study. *Journal of Clinical Medicine* **2021**, *10*, doi:10.3390/jcm10225298.
38. Porto, M.H.; Delgado, T.; Aguirre-Jaime, A.; Ramos, M.J.; Campos, S.; Acosta, O.; Llanos, A.B.; Lecuona, M. Patients at risk of pulmonary fibrosis Post Covid-19: Epidemiology, pulmonary sequelaes and humoral response. 2022; 10.1101/2022.03.04.22271920.
39. Attauabi, M.; Dahlerup, J.F.; Poulsen, A.; Hansen, M.R.; Vester-Andersen, M.K.; Eraslan, S.; Prahm, A.P.; Pedersen, N.; Larsen, L.; Jess, T., et al. Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases - A Danish Prospective Population-Based Cohort Study with Individual-Level Data. *Journal of Crohn's and Colitis* **2022**, *16*, 757-767, doi:10.1093/ecco-jcc/jjab192.
40. Hossain, M.A.; Hossain, K.M.A.; Saunders, K.; Uddin, Z.; Walton, L.M.; Raigangar, V.; Sakel, M.; Shafin, R.; Hossain, M.S.; Kabir, M.F., et al. Prevalence of Long COVID symptoms in Bangladesh: A prospective Inception Cohort Study of COVID-19 survivors. *BMJ Global Health* **2021**, *6*, doi:10.1136/bmjgh-2021-006838.
41. Eloy, P.; Tardivon, C.; Martin-Blondel, G.; Isnard, M.; Turnier, P.L.; Marechal, M.L.; CabiÉ, A.; Launay, O.; Tattevin, P.; Senneville, E., et al. Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19: a prospective cohort study. *International Journal of Infectious Diseases* **2021**, *112*, 247-253, doi:10.1016/j.ijid.2021.09.011.
42. Duggal, P.; Penson, T.; Manley, H.N.; Vergara, C.; Munday, R.M.; Duchen, D.; Linton, E.A.; Zurn, A.; Keruly, J.C.; Mehta, S.H., et al. Post-sequelae symptoms and comorbidities after COVID-19. *Journal of Medical Virology* **2022**, *94*, 2060-2066, doi:10.1002/jmv.27586.
43. Mónica, R.-S.; Maribel, Q.-F.; Javier, J.; Isabel, L.-M.; Rocío, T.; Rocío, A.; Javier, G.-P.F. Cardiac complications in a geriatric population hospitalized with COVID-19: The OCTA-COVID cohort. *Revista Española de Geriatría y Gerontología* **2022**, *57*, 63-70, doi:https://doi.org/10.1016/j.regg.2022.01.003.
44. Peter, R.S.; Nieters, A.; Kräusslich, H.G.; Brockmann, S.O.; Göpel, S.; Kindle, G.; Merle, U.;

Steinacker, J.M.; Rothenbacher, D.; Kern, W.V., et al. Prevalence, determinants, and impact on general health and working capacity of post-acute sequelae of COVID-19 six to 12 months after infection: a population-based retrospective cohort study from southern Germany. 2022; 10.1101/2022.03.14.22272316.

45. Robey, R.C.; Kemp, K.; Hayton, P.; Mudawi, D.; Wang, R.; Greaves, M.; Yioe, V.; Rivera-Ortega, P.; Avram, C.; Chaudhuri, N. Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. *Advances in Therapy* **2021**, *38*, 4505-4519, doi:10.1007/s12325-021-01833-4.
46. Titze-de-Almeida, R.; da Cunha, T.R.; dos Santos Silva, L.D.; Ferreira, C.S.; Silva, C.P.; Ribeiro, A.P.; de Castro Moreira Santos Júnior, A.; de Paula Brandão, P.R.; Silva, A.P.B.; da Rocha, M.C.O., et al. Persistent, new-onset symptoms and mental health complaints in Long COVID in a Brazilian cohort of non-hospitalized patients. *BMC Infectious Diseases* **2022**, *22*, doi:10.1186/s12879-022-07065-3.
47. Zayet, S.; Zahra, H.; Royer, P.Y.; Tipirdamaz, C.; Mercier, J.; Gendrin, V.; Lepiller, Q.; Marty-Quinternet, S.; Osman, M.; Belfeki, N., et al. Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France. *Microorganisms* **2021**, *9*, doi:10.3390/microorganisms9081719.
48. Liao, X.; Li, D.; Liu, Z.; Ma, Z.; Zhang, L.; Dong, J.; Shi, Y.; Gu, X.; Zheng, G.; Huang, L., et al. Pulmonary Sequelae in Patients After Recovery From Coronavirus Disease 2019: A Follow-Up Study With Chest CT. *Frontiers in Medicine* **2021**, *8*, doi:10.3389/fmed.2021.686878.
49. Li, Y.; Han, X.; Huang, J.; Alwalid, O.; Jia, X.; Yuan, M.; Cao, Y.; Shao, G.; Cui, Y.; Liu, J.; et al. Follow-up study of pulmonary sequelae in discharged COVID-19 patients with diabetes or secondary hyperglycemia. Eur. J. Radiol. **2021**, 144, 109997. https://doi.org/10.1016/j.ejrad.2021.109997..
50. Aparisi, Á.; Ybarra-Falcón, C.; García-Gómez, M.; Tobar, J.; Iglesias-Echeverría, C.; Jaurrieta-Largo, S.; Ladrón, R.; Uribarri, A.; Catalá, P.; Hinojosa, W., et al. Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation. *J Clin Med* **2021**, *10*, doi:10.3390/jcm10122591.
51. Romero-Duarte, Á.; Rivera-Izquierdo, M.; Guerrero-Fernández de Alba, I.; Pérez-Contreras, M.; Fernández-Martínez, N.F.; Ruiz-Montero, R.; Serrano-Ortiz, Á.; González-Serna, R.O.; Salcedo-Leal, I.; Jiménez-Mejías, E., et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. *BMC Medicine* **2021**, *19*, doi:10.1186/s12916-021-02003-7.